Product Name :
Anti-ITGALand ITGB2(Rovelizumab Biosimilar) Antibody
Applications:
ELISA,Flow Cyt
Reactivity :
Human ITGAL/CD11A/LFA1A and ITGB2/CD18
Conjugate:
Unconjugated
Advantages :
High lot-to-lot consistencyIncreased sensitivity and higher affinityAnimal-free production
Description:
| Description: Anti-ITGALand ITGB2(Rovelizumab Biosimilar) Antibody is a biosimilar antibody directed against Human ITGAL/CD11A/LFA1A and ITGB2/CD18. | Isotype: Human IgG4 | Conjugate: Unconjugated | Specificity: Human ITGAL/CD11A/LFA1A and ITGB2/CD18 | Clonality: Monoclonal | Purity: Recombinant Expression and Affinity purified | Concentration: 1mg/ml | Formation: Liquid, 10mM PBS (pH 7.{{1937235-76-1} site|{1937235-76-1} Protocol|{1937235-76-1} Data Sheet|{1937235-76-1} supplier} 5) | Storage: Store at –20 °C, (Avoid freeze/thaw cycles)
Description2 :
Anti-ITGALand ITGB2(Rovelizumab Biosimilar) Antibody is a biosimilar antibody directed against Human ITGAL/CD11A/LFA1A and ITGB2/CD18.{{1794941-44-8} site|{1794941-44-8} Protocol|{1794941-44-8} In stock|{1794941-44-8} custom synthesis}
Immunogen:
Host :
Isotype:
Human IgG4
Purity :
Recombinant Expression and Affinity purified
Buffer :
Storage :
Function:
ELISA: 1:5000-1:20000Flow Cyt: 1:200-1:1000Other tested applications.PMID:28846358 Dilution factors are presented in the form of a range because the optimal dilution is a function of many factors, such as antigen density, permeability, etc. The actual dilution used must be determined empirically.
